Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $44.39.
A number of brokerages have issued reports on GMAB. TD Cowen lifted their target price on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday. Morgan Stanley set a $42.00 price target on shares of Genmab A/S in a research report on Tuesday, October 20th. New Street Research set a $43.00 price target on shares of Genmab A/S in a research report on Wednesday, July 22nd. Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Finally, Truist Financial lifted their price objective on Genmab A/S from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, October 7th.
View Our Latest Report on Genmab A/S
Genmab A/S Trading Up 28.3%
Shares of GMAB stock opened at $57.29 on Monday. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $59.97. The stock has a market cap of $35.75 billion, a P/E ratio of 45.11, a P/E/G ratio of 2.01 and a beta of 0.81. The business has a fifty day simple moving average of $36.20 and a 200-day simple moving average of $30.36. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.
Genmab A/S (NASDAQ:GMAB – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. On average, analysts forecast that Genmab A/S will post 1.22 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Genmab A/S
Institutional investors have recently made changes to their positions in the stock. Park Avenue Securities LLC grew its holdings in Genmab A/S by 2.4% in the third quarter. Park Avenue Securities LLC now owns 11,258 shares of the company’s stock valued at $402,000 after purchasing an additional 265 shares during the period. Personal CFO Solutions LLC boosted its holdings in Genmab A/S by 3.7% in the first quarter. Personal CFO Solutions LLC now owns 10,866 shares of the company’s stock valued at $292,000 after acquiring an additional 386 shares during the last quarter. Versant Capital Management Inc increased its stake in Genmab A/S by 4.5% during the third quarter. Versant Capital Management Inc now owns 12,235 shares of the company’s stock worth $436,000 after acquiring an additional 523 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 16.4% in the 2nd quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock worth $109,000 after purchasing an additional 561 shares during the period. Finally, Summitry LLC grew its stake in Genmab A/S by 5.3% during the first quarter. Summitry LLC now owns 11,170 shares of the company’s stock worth $300,000 after buying an additional 567 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.
Key Stories Impacting Genmab A/S
Here are the key news stories impacting Genmab A/S this week:
- Positive Sentiment: Genmab reported that the Phase 3 LiGeR-HN1 trial met both primary endpoints in first-line, PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma. Petosemtamab combined with Merck’s pembrolizumab reduced the risk of death by 50% versus pembrolizumab alone, with a statistically significant improvement in overall survival and objective response rate, regardless of patients’ HPV status. Genmab Phase 3 trial announcement
- Positive Sentiment: The results support expectations that petosemtamab could become a meaningful commercial product and potentially establish a new treatment standard. Analysts described the results as a significant “hat trick,” while reports highlighted the drug’s potential in combination with Keytruda. Barron’s report on Genmab’s record high
- Positive Sentiment: JPMorgan upgraded its rating on GMAB, and TD Cowen said the stock could rise, adding to the positive analyst sentiment. Heavy call-option activity also indicates strong speculative interest following the clinical announcement. JPMorgan rating upgrade
- Neutral Sentiment: Genmab plans to discuss the results with global regulators and submit the full dataset for presentation at a future medical meeting. Investors still lack the complete efficacy and safety details, and regulatory approval and commercialization remain ahead. Genmab Phase III data discussion
Genmab A/S Company Profile
Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.
Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.
Featured Articles
- Five stocks we like better than Genmab A/S
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
